Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2019 Publisher: Napp Pharmaceuticals Ltd, Cambridge Science Park, Milton Road, Cambridge, CB4 0GW, United Kingdom
MST CONTINUS suspension 20, 30, 60, 100, 200 mg.
| Pharmaceutical Form |
|---|
|
Prolonged release granules for oral suspension. Pink granules. |
Each sachet contains Morphine equivalent to Morphine Sulfate 20, 30, 60, 100 and 200 mg.
Excipients with known effect:
Ponceau 4R (E124)
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Morphine |
Morphine is a narcotic analgesic obtained from opium. Morphine acts as an agonist at opiate receptors in the CNS particularly Mu and to a lesser extent Kappa receptors. Mu receptors are thought to mediate supraspinal analgesia, respiratory depression and euphoria, and Kappa receptors, spinal analgesia, miosis and sedation. |
| List of Excipients |
|---|
|
Dowex 50WX8 100-200 mesh cationic exchange resin |
Pack type: surlyn lined, laminated aluminium foil sachets coated with polyethylene and clay coated Kraft paper.
Pack size: Boxboard cartons of 10, 20, 30, 60 sachets or medical sample packs of up to 14 sachets.
Not all pack sizes may be marketed.
Napp Pharmaceuticals Ltd, Cambridge Science Park, Milton Road, Cambridge, CB4 0GW, United Kingdom
PL 16950/0030 -0034
14 January 1994/19 November 2006
| Drug | Countries | |
|---|---|---|
| MST CONTINUS | Cyprus, Estonia, Croatia, Ireland, Malta, Poland, United Kingdom, South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
